Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423901 | 0.91 | SIGMAR1 (0.41) | OPRL1OPRM1OPRK1POLBSIGMAR1 | |
| SCHEMBL824131 | 0.80 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13837573 | 0.77 | DPP4 (0.41) | OPRL1OPRM1SIGMAR1CHRM1 | |
| SCHEMBL24585209 | 0.76 | OPRM1 (0.54) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL22814930 | 0.76 | OPRM1 (0.40) | OPRL1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL10119962 | 0.76 | OPRL1 (0.43) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL25784704 | 0.75 | NCF1 (0.37) | OPRM1KDM4EALDH1A1CHRM1 | |
| SCHEMBL6263030 | 0.75 | NCF1 (0.37) | OPRM1KDM4EALDH1A1CHRM1 | |
| SCHEMBL10271087 | 0.74 | OPRM1 (0.39) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL28876612 | 0.74 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | OPRL1 4259/4885OPRM1 4824/4885OPRK1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.